AR101393A1 - COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2 - Google Patents

COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2

Info

Publication number
AR101393A1
AR101393A1 ARP150102462A ARP150102462A AR101393A1 AR 101393 A1 AR101393 A1 AR 101393A1 AR P150102462 A ARP150102462 A AR P150102462A AR P150102462 A ARP150102462 A AR P150102462A AR 101393 A1 AR101393 A1 AR 101393A1
Authority
AR
Argentina
Prior art keywords
alkyl
monohalo
polyhalo
compounds
4oxy
Prior art date
Application number
ARP150102462A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR101393A1 publication Critical patent/AR101393A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP150102462A 2014-08-01 2015-07-31 COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2 AR101393A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14179599 2014-08-01

Publications (1)

Publication Number Publication Date
AR101393A1 true AR101393A1 (es) 2016-12-14

Family

ID=51257438

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102462A AR101393A1 (es) 2014-08-01 2015-07-31 COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2

Country Status (15)

Country Link
US (1) US10112949B2 (enExample)
EP (1) EP3174880B1 (enExample)
JP (1) JP6615864B2 (enExample)
KR (1) KR102531693B1 (enExample)
CN (1) CN106573935B (enExample)
AR (1) AR101393A1 (enExample)
AU (1) AU2015295299B2 (enExample)
BR (1) BR112017001998A2 (enExample)
CA (1) CA2954218C (enExample)
EA (1) EA031038B1 (enExample)
ES (1) ES2702192T3 (enExample)
JO (1) JO3601B1 (enExample)
MX (1) MX2017001453A (enExample)
TW (1) TWI696625B (enExample)
WO (1) WO2016016381A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JP6861154B2 (ja) 2014-12-03 2021-04-21 ヤンセン ファーマシューティカ エヌ.ベー. 放射標識されたmGluR2 PETリガンド
CA2967153A1 (en) * 2014-12-03 2016-06-09 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-.alpha.]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
ES2820823T3 (es) 2015-12-18 2021-04-22 Janssen Pharmaceutica Nv Ligandos PET mGluR2/3 radiomarcados
EP3389727B1 (en) * 2015-12-18 2020-08-12 Janssen Pharmaceutica NV Radiolabelled mglur2/3 pet ligands
SG11202004484UA (en) 2017-11-24 2020-06-29 Sumitomo Dainippon Pharma Co Ltd 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004054665A1 (de) * 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
JP4801724B2 (ja) * 2005-03-23 2011-10-26 エフ.ホフマン−ラ ロシュ アーゲー mGluR2アンタゴニストとしてのアセチレニル−ピラゾロ−ピリミジン誘導体
AU2010246609B2 (en) 2009-05-12 2013-09-05 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
US8592422B2 (en) * 2010-12-17 2013-11-26 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors
WO2012172093A1 (en) * 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
EP2775841B1 (en) 2011-11-03 2017-09-13 Merck Sharp & Dohme Corp. QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
US20130345204A1 (en) 2012-06-20 2013-12-26 Vanderbilt University Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
AU2013277152A1 (en) * 2012-06-20 2015-01-22 Vanderbilt University Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mGluR5 receptors
WO2013192350A1 (en) * 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
JP2015534993A (ja) 2012-10-23 2015-12-07 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffma 自閉症性障害の処置のためのmGlu2/3アンタゴニスト
EP3174882B1 (en) * 2014-08-01 2018-11-07 Janssen Pharmaceutica NV 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors

Also Published As

Publication number Publication date
AU2015295299A1 (en) 2017-01-19
US20180222908A1 (en) 2018-08-09
CN106573935B (zh) 2020-01-17
CA2954218C (en) 2022-11-29
EA201692496A1 (ru) 2017-06-30
KR20170032464A (ko) 2017-03-22
WO2016016381A1 (en) 2016-02-04
JP6615864B2 (ja) 2019-12-04
US10112949B2 (en) 2018-10-30
AU2015295299B2 (en) 2019-05-02
EP3174880A1 (en) 2017-06-07
JP2017523201A (ja) 2017-08-17
EA031038B1 (ru) 2018-11-30
JO3601B1 (ar) 2020-07-05
ES2702192T3 (es) 2019-02-27
BR112017001998A2 (pt) 2017-12-12
TW201609742A (zh) 2016-03-16
EP3174880B1 (en) 2018-09-26
CA2954218A1 (en) 2016-02-04
MX2017001453A (es) 2017-05-11
KR102531693B1 (ko) 2023-05-10
TWI696625B (zh) 2020-06-21
CN106573935A (zh) 2017-04-19

Similar Documents

Publication Publication Date Title
AR101393A1 (es) COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2
AR132512A2 (es) Compuesto de aminoalquilbenzotiazepina, composición farmacéutica que lo comprende y método para tratar el estreñimiento en un sujeto que lo necesita
CU24517B1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
AR101392A1 (es) COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR101175A1 (es) Imidazopiridinas e imidazopirazinas como inhibidores de lsd1
CO2018002829A2 (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm)
MX378315B (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
EA201791304A1 (ru) Производные изохинолина для лечения вич
BR112017000943A2 (pt) ácidos carboxílicos heterocíclicos como ativadores de guanilato ciclase solúveis
EA201592252A1 (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
MX2017001554A (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias.
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
AR112264A1 (es) Derivados de oxoftalazina y oxocinolina como antagonistas de los receptores s1p, composición farmacéutica que los comprende y su uso para el tratamiento de enfermedades fibróticas, autoinmunes y proliferativas
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
AR092809A1 (es) 3,5-diaminopirazol como inhibidor de quinasa
AR075368A1 (es) Inhibidores de glicosilceramida sintasa
PE20150182A1 (es) Compuestos de fenoxietil piperidina
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
TW201613914A (en) 2-acylaminothiazole derivative or salt thereof
AR091520A1 (es) Inhibidores piranopiridona de tanquirasa
AR091731A1 (es) Antagonistas del receptor de mineralocorticoides

Legal Events

Date Code Title Description
FB Suspension of granting procedure